Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster.
The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website.
By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.
[h=1]Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season[/h] [h=4]24 September 2015[/h] It is recommended that trivalent vaccines for use in the 2016 influenza season (southern hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Hong Kong/4801/2014 (H3N2)-like virus;
a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.
[h=4]For more information[/h]
[h=4]Candidate vaccine viruses and potency testing reagents for development and production of vaccines for use in the southern hemisphere 2016 influenza season[/h]
WHO | Antigenic and genetic characteristics of zoonotic influenza viruses and candidate vaccine viruses developed for potential use in human vaccines
24 September 2015
A(H3N2) viruses collected from February 2015 to August 2015 fell into the phylogenetic clades 3C.2 and 3C.3. Viruses in sub-clade 3C.2a are now predominant in all regions of the world. Sub-clade 3C.3a and 3C.3b viruses continued to circulate but represented the minority of viruses in this reporting period.
Antigenic characteristics of A(H3N2) viruses were assessed with panels of post-infection ferret antisera in HI and virus neutralization assays. Antigenic characterization of 3C.2a viruses remained technically challenging because many viruses had low or undetectable haemagglutination activity and required the use of modified HI and virus neutralization assays for analysis. Most recent A(H3N2) 3C.2a viruses were well inhibited by ferret antisera raised against cell-propagated reference
A/Switzerland/9715293/2013 (3C.3a) virus, indicating that 3C.2a and 3C.3a viruses remain antigenically related. Ferret antisera raised against reference cell-propagated 3C.2a viruses also well inhibited a majority of viruses tested, although inhibition was somewhat reduced against 3C.3a viruses, indicating that some 3C.2a and 3C.3a viruses were antigenically distinguishable. Such changes have been particularly problematic for recent A(H3N2) viruses. Ferret antisera raised against egg-propagated 3C.2a viruses, including A/Hong Kong/4801/2014, generally inhibited recently circulating
viruses better than antisera raised to egg-propagated A/Switzerland/9715293/2013 virus (Table 1).
